



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an independent Licensee of the Blue Cross and Blue Shield Association

Medical Policy

Medical Technology Assessment Investigational (Non-Covered) Services List

The services listed below are considered investigational (non-covered) because they do not meet the Blue Cross Blue Shield Medical Technology Assessment Guidelines. The five criteria that make up the guidelines appear on Medical Policy #350:

Medical Policy #400, Medical Technology Assessment Investigational (Non-Covered) Services List includes entries only for non-covered services that do not have an associated BCBSMA medical policy. The most accurate way of determining whether a service is covered or not covered is to perform a keyword or a procedure code search on our medical policy page online.

<https://www.bluecrossma.org/medical-policies/>

All coverage is based on a member’s plan documents (subscriber certificate, evidence of coverage). If there is a difference between the coverage in this policy and a member’s documents, the plan documents will be used to determine coverage.

Category III CPT Codes

ALL category III CPT Codes are **non-covered** unless they are explicitly described as “medically necessary” in a BCBSMA medical policy. To search for a particular code, click the following link: <https://www.bluecrossma.org/medical-policies/> and type the code in the search box on the page. Consult the coverage statement of any associated medical policy.

If there is no associated policy, the code is non-covered.

Table of Contents

Table 1: Non-Covered CPT Codes and Code Descriptions	1
Table 2: Non-Covered Procedure Narratives	8
Table 3: Non-Covered HCPCS Codes and Code Descriptions.....	10

Table 1: Non-Covered CPT Codes and Code Descriptions

The following CPT codes and procedure narratives are investigational (not covered) for Commercial Products and for Medicare HMO Blue and Medicare PPO Blue, because they do not meet our Medical Technology Assessment Guidelines [350](#).

CPT codes	Code Description
19294	Preparation of tumor cavity, with placement of a radiation therapy applicator for intraoperative radiation therapy (IORT) concurrent with partial mastectomy (List separately in addition to code for primary procedure)

30210	Displacement therapy (Proetz type)
37187	Percutaneous transluminal mechanical thrombectomy, vein(s), including intraprocedural pharmacological thrombolytic injections and fluoroscopic guidance
37188	Percutaneous transluminal mechanical thrombectomy, vein(s) including intraprocedural pharmacological thrombolytic injections and fluoroscopic guidance, repeat treatment on subsequent day during course of thrombolytic therapy
37790	Penile venous occlusive procedure
64912	Nerve repair; with nerve allograft, each nerve, first strand (cable)
64913	Nerve repair; with nerve allograft, each additional strand (List separately in addition to code for primary procedure)
70371	Complex dynamic pharyngeal and speech evaluation by cine or video recording - not covered for commercial products only
70557	Magnetic resonance (eg, proton) imaging, brain (including brain stem and skull base), during open intracranial procedure (eg, to assess for residual tumor or residual vascular malformation); without contrast material
70558	Magnetic resonance (eg, proton) imaging, brain (including brain stem and skull base), during open intracranial procedure (eg, to assess for residual tumor or residual vascular malformation); with contrast material(s)
70559	Magnetic resonance (eg, proton) imaging, brain (including brain stem and skull base), during open intracranial procedure (eg, to assess for residual tumor or residual vascular malformation); without contrast material(s), followed by contrast material(s) and further sequences
76376	3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; not requiring image postprocessing on an independent workstation - not covered for commercial products only
76377	3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstation- not covered for commercial products only
80187	Posaconazole
80235	Lacosamide
80280	Vedolizumab
80285	Voriconazole
81506	Endocrinology (type 2 diabetes), biochemical assays of seven analytes (glucose, HbA1c, insulin, hs-CRP, adiponectin, ferritin, interleukin 2-receptor alpha), utilizing serum or plasma, algorithm reporting a risk score
82107	Alpha-fetoprotein (AFP); AFP-L3 fraction isoform and total AFP (including ratio)
82610	Cystatin C
82656	Elastase, pancreatic (EL-1), fecal, qualitative or semi-quantitative
82777	Galectin-3
83631	Lactoferrin, fecal; quantitative
83876	Myeloperoxidase (MPO)
83951	Oncoprotein; des-gamma-carboxy-prothrombin (DCP)
84145	Procalcitonin (PCT)
84449	Transcortin (cortisol binding globulin)
86001	Allergen specific IgG quantitative or semiquantitative, each allergen
86486	Skin test; unlisted antigen, each
87801	Infectious agent detection by nucleic acid (DNA and RNA), multiple organisms, amplified probe(S) technique - not covered for commercial products only
91132	Electrogastrography, diagnostic, transcutaneous
91133	Electrogastrography, diagnostic, transcutaneous; with provocative testing
87809	Infectious agent antigen detection by immunoassay with direct optical observation; adenovirus

92145	Corneal hysteresis determination, by air impulse stimulation, unilateral or bilateral, with interpretation and report
92520	Laryngeal function studies - not covered for commercial products only
92572	Staggered spondaic word test - not covered for commercial products only
92576	Synthetic sentence identification test
93998	Unlisted noninvasive vascular diagnostic study
95060	Ophthalmic mucous membrane tests - not covered for commercial products only
95065	Direct nasal mucous membrane test - not covered for commercial products only
96146	Psychological or neuropsychological test administration, with single automated, standardized instrument via electronic platform, with automated result only
96904	Whole body integumentary photography, for monitoring of high-risk patients with dysplastic nevus syndrome or a history of dysplastic nevi, or patients with a personal or familial history of melanoma
99605	Medication therapy management service(s) provided by a pharmacist, individual, face-to-face with patient, with assessment and intervention if provided; initial 15 minutes, new patient
99606	Medication therapy management service(s) provided by a pharmacist, individual, face-to-face with patient, with assessment and intervention if provided; initial 15 minutes, established patient
99607	Medication therapy management service(s) provided by a pharmacist, individual, face-to-face with patient, with assessment and intervention if provided; each additional 15 minutes (List separately in addition to code for primary service)
0014M	Liver disease, analysis of 3 biomarkers (hyaluronic acid [HA], procollagen III amino terminal peptide [PIIINP], tissue inhibitor of metalloproteinase 1[TIMP-1]), using immunoassays, utilizing serum, prognostic algorithm reported as a risk score and risk of liver fibrosis and liver-related clinical events within 5 years
0002U	Oncology (colorectal), quantitative assessment of three urine metabolites (ascorbic acid, succinic acid and carnitine) by liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring acquisition, algorithm reported as likelihood of adenomatous polyps
0007U	Drug test(s), presumptive, with definitive confirmation of positive results, any number of drug classes, urine, includes specimen verification including DNA authentication in comparison to buccal DNA, per date of service
0008U	Helicobacter pylori detection and antibiotic resistance, dna, 16s and 23s rrna, gyra, pbp1, rdx and rpob, next generation sequencing, formalin-fixed paraffin-embedded or fresh tissue, predictive, reported as positive or negative for resistance to clarithromycin, fluoroquinolones, metronidazole, amoxicillin, tetracycline and rifabutin
0009U	Oncology (breast cancer), ERBB2 (HER2) copy number by FISH, tumor cells from formalin fixed paraffin embedded tissue isolated using image-based dielectrophoresis (DEP) sorting, reported as ERBB2 gene amplified or non-amplified
0010U	Infectious disease (bacterial), strain typing by whole genome sequencing, phylogenetic-based report of strain relatedness, per submitted isolate
0011U	Prescription drug monitoring, evaluation of drugs present by LC-MS/MS, using oral fluid, reported as a comparison to an estimated steady-state range, per date of service including all drug compounds and metabolites
0020U	Drug test(s), presumptive, with definitive confirmation of positive results, any number of drug classes, urine, with specimen verification including DNA authentication in comparison to buccal DNA, per date of service
0024U	Glycosylated acute phase proteins (GlycA), nuclear magnetic resonance spectroscopy, quantitative
0025U	Tenofovir, by liquid chromatography with tandem mass spectrometry (LC-MS/MS), urine, quantitative
0035U	Neurology (prion disease), cerebrospinal fluid, detection of prion protein by quaking-induced conformational conversion, qualitative
0038U	Vitamin D, 25 hydroxy D2 and D3, by LC-MS/MS, serum microsample, quantitative

0039U	Deoxyribonucleic acid (DNA) antibody, double stranded, high avidity
0043U	Tick-borne relapsing fever Borrelia group, antibody detection to 4 recombinant protein groups, by immunoblot, IgM
0044U	Tick-borne relapsing fever Borrelia group, antibody detection to 4 recombinant protein groups, by immunoblot, IgG
0051U	Prescription drug monitoring, evaluation of drugs present by LC-MS/MS, urine, 31 drug panel, reported as quantitative results, detected or not detected, per date of service
0054U	Prescription drug monitoring, 14 or more classes of drugs and substances, definitive tandem mass spectrometry with chromatography, capillary blood, quantitative report with therapeutic and toxic ranges, including steady-state range for the prescribed dose when detected, per date of service
0061U	Transcutaneous measurement of five biomarkers (tissue oxygenation [StO ₂], oxyhemoglobin [ctHbO ₂], deoxyhemoglobin [ctHbR], papillary and reticular dermal hemoglobin concentrations [ctHb1 and ctHb2]), using spatial frequency domain imaging (SFDI) and multi-spectral analysis
0063U	Neurology (autism), 32 amines by LC-MS/MS, using plasma, algorithm reported as metabolic signature associated with autism spectrum disorder
0064U	Antibody, Treponema pallidum, total and rapid plasma reagin (RPR), immunoassay, qualitative
0065U	Syphilis test, non-treponemal antibody, immunoassay, qualitative (RPR)
0066U	Placental alpha-micro globulin-1 (PAMG-1), immunoassay with direct optical observation, cervico-vaginal fluid, each specimen
0067U	Oncology (breast), immunohistochemistry, protein expression profiling of 4 biomarkers (matrix metalloproteinase-1 [MMP-1], carcinoembryonic antigen-related cell adhesion molecule 6 [CEACAM6], hyaluronoglucosaminidase [HYAL1], highly expressed in cancer protein [HEC1]), formalin-fixed paraffin-embedded precancerous breast tissue, algorithm reported as carcinoma risk score
0068U	Candida species panel (C. albicans, C. glabrata, C. parapsilosis, C. kruseii, C. tropicalis, and C. auris), amplified probe technique with qualitative report of the presence or absence of each species
0077U	Immunoglobulin paraprotein (M-protein), qualitative, immunoprecipitation and mass spectrometry, blood or urine, including isotype
0082U	Drug test(s), definitive, 90 or more drugs or substances, definitive chromatography with mass spectrometry, and presumptive, any number of drug classes, by instrument chemistry analyzer (utilizing immunoassay), urine, report of presence or absence of each drug, drug metabolite or substance with description and severity of significant interactions per date of service
0083U	Oncology, response to chemotherapy drugs using motility contrast tomography, fresh or frozen tissue, reported as likelihood of sensitivity or resistance to drugs or drug combinations
0084U	Red blood cell antigen typing, DNA, genotyping of 10 blood groups with phenotype prediction of 37 red blood cell antigens
0086U	Infectious disease (bacterial and fungal), organism identification, blood culture, using rRNA FISH, 6 or more organism targets, reported as positive or negative with phenotypic minimum inhibitory concentration (MIC)-based antimicrobial susceptibility
0091U	Oncology (colorectal) screening, cell enumeration of circulating tumor cells, utilizing whole blood, algorithm, for the presence of adenoma or cancer, reported as a positive or negative result
0093U	Prescription drug monitoring, evaluation of 65 common drugs by LC-MS/MS, urine, each drug reported detected or not detected
0095U	Inflammation (eosinophilic esophagitis), ELISA analysis of eotaxin-3 (CCL26 [C-C motif chemokine ligand 26]) and major basic protein (PRG2 [proteoglycan 2, pro eosinophil major basic protein]), specimen obtained by swallowed nylon string, algorithm reported as predictive probability index for active eosinophilic esophagitis

0096U	Human papillomavirus (HPV), high-risk types (ie, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68), male urine
0097U	Gastrointestinal pathogen, multiplex reverse transcription and multiplex amplified probe technique, multiple types or subtypes, 22 targets (Campylobacter [<i>C. jejuni</i> / <i>C. coli</i> / <i>C. upsaliensis</i>], Clostridium difficile [<i>C. difficile</i>] toxin A/B, Plesiomonas shigelloides, Salmonella, Vibrio [<i>V. parahaemolyticus</i> / <i>V. vulnificus</i> / <i>V. cholerae</i>], including specific identification of Vibrio cholerae, Yersinia enterocolitica, Enterococci, Enteropathogenic Escherichia coli [EPEC], Enterotoxigenic Escherichia coli [ETEC] It/st, Shiga-like toxin-producing Escherichia coli [STEC] stx1/stx2 [including specific identification of the E. coli O157 serogroup within STEC], Shigella/Enteroinvasive Escherichia coli [EIEC], Cryptosporidium, Cyclospora cayentanensis, Entamoeba histolytica, Giardia lamblia [also known as G. intestinalis and G. duodenalis], adenovirus F 40/41, astrovirus, norovirus GI/GII, rotavirus A, sapovirus [Genogroups I, II, IV, and V])
0105U	Nephrology (chronic kidney disease), multiplex electrochemiluminescent immunoassay (ECLIA) of tumor necrosis factor receptor 1A, receptor superfamily 2 (TNFR1, TNFR2), and kidney injury molecule-1 (KIM-1) combined with longitudinal clinical data, including APOL1 genotype if available, and plasma (isolated fresh or frozen), algorithm reported as probability score for rapid kidney function decline (RKFD)
0106U	Gastric emptying, serial collection of 7 timed breath specimens, non-radioisotope carbon-13 (13C) spirulina substrate, analysis of each specimen by gas isotope ratio mass spectrometry, reported as rate of 13CO2 excretion
0108U	Gastroenterology (Barrett's esophagus), whole slide–digital imaging, including morphometric analysis, computer-assisted quantitative immunolabeling of 9 protein biomarkers (p16, AMACR, p53, CD68, COX-2, CD45RO, HIF1a, HER-2, K20) and morphology, formalin-fixed paraffin-embedded tissue, algorithm reported as risk of progression to high-grade dysplasia or cancer
0109U	Infectious disease (Aspergillus species), real-time PCR for detection of DNA from 4 species (<i>A. fumigatus</i> , <i>A. terreus</i> , <i>A. niger</i> , and <i>A. flavus</i>), blood, lavage fluid, or tissue, qualitative reporting of presence or absence of each species
0110U	Prescription drug monitoring, one or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detected
0112U	Infectious agent detection and identification, targeted sequence analysis (16S and 18S rRNA genes) with drug-resistance gene
0116U	Prescription drug monitoring, enzyme immunoassay of 35 or more drugs confirmed with LC-MS/MS, oral fluid, algorithm results reported as a patient-compliance measurement with risk of drug to drug interactions for prescribed medications
0117U	Pain management, analysis of 11 endogenous analytes (methylmalonic acid, xanthurenic acid, homocysteine, pyroglutamic acid, vanilmandelate, 5-hydroxyindoleacetic acid, hydroxymethylglutarate, ethylmalonate, 3-hydroxypropyl mercapturic acid (3-HPMA), quinolinic acid, kynurenic acid), LC-MS/MS, urine, algorithm reported as a pain-index score with likelihood of atypical biochemical function associated with pain
0119U	Cardiology, ceramides by liquid chromatography–tandem mass spectrometry, plasma, quantitative report with risk score for major cardiovascular events
0121U	Sickle cell disease, microfluidic flow adhesion (VCAM-1), whole blood
0122U	Sickle cell disease, microfluidic flow adhesion (P-Selectin), whole blood
0123U	Mechanical fragility, RBC, shear stress and spectral analysis profiling
0126U	Fetal congenital abnormalities and perinatal complications, biochemical assays of 5 analytes (free beta-hCG, PAPP-A, AFP, placental growth factor, and inhibin-A), time-resolved fluorescence immunoassay, includes qualitative assessment of Y chromosome in cell-free fetal DNA, maternal serum and plasma, predictive algorithm reported as a risk scores for fetal trisomies 13/18, 21, and preeclampsia

0139U	Neurology (autism spectrum disorder [ASD]), quantitative measurements of 6 central carbon metabolites (ie, α -ketoglutarate, alanine, lactate, phenylalanine, pyruvate, and succinate), LC-MS/MS, plasma, algorithmic analysis with result reported as negative or positive (with metabolic subtypes of ASD)
0143U	Drug assay, definitive, 120 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service u(For additional PLA code with identical clinical descriptor, see0150U. See Appendix O to determine appropriate code assignment)
0144U	Drug assay, definitive, 160 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service
0145U	Drug assay, definitive, 65 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service
0146U	Drug assay, definitive, 80 or more drugs or metabolites, urine, by quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service
0147U	Drug assay, definitive, 85 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service
0148U	Drug assay, definitive, 100 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service
0149U	Drug assay, definitive, 60 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service
0150U	Drug assay, definitive, 120 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service u(For additional PLA code with identical clinical descriptor, see0143U. See Appendix O to determine appropriate code assignment)
0151U	Infectious disease (bacterial or viral respiratory tract infection), pathogen specific nucleic acid (DNA or RNA), 33 targets, real-time semi-quantitative PCR, bronchoalveolar lavage, sputum, or endotracheal aspirate, detection of 33 organismal and antibiotic resistance genes with limited semi-quantitative results
0152U	Infectious disease (bacteria, fungi, parasites, and DNA viruses), DNA, PCR and next-generation sequencing, plasma, detection of >1,000 potential microbial organisms for significant positive pathogens
0163U	Oncology (colorectal) screening, biochemical enzyme-linked immunosorbent assay (ELISA) of 3 plasma or serum proteins (teratocarcinoma derived growth factor-1 [TDGF-1, Cripto-1], carcinoembryonic antigen [CEA], extracellular matrix protein [ECM]), with demographic data (age, gender, CRC-screening compliance) using a proprietary algorithm and reported as likelihood of CRC or advanced adenomas
0164U	Gastroenterology (irritable bowel syndrome [IBS]), immunoassay for anti-CdtB and anti-vinculin antibodies, utilizing plasma, algorithm for elevated or not elevated qualitative results
0165U	Peanut allergen-specific IgE and quantitative assessment of 64 epitopes using enzyme-linked immunosorbent assay (ELISA), blood, individual epitope results and interpretation

0166U	Liver disease, 10 biochemical assays (α 2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, GGT, ALT, AST, triglycerides, cholesterol, fasting glucose) and biometric and demographic data, utilizing serum, algorithm reported as scores for fibrosis, necroinflammatory activity, and steatosis with a summary interpretation
0174U	Oncology (solid tumor), mass spectrometric 30 protein targets, formalin-fixed paraffin-embedded tissue, prognostic and predictive algorithm reported as likely, unlikely, or uncertain benefit of 39 chemotherapy and targeted therapeutic oncology agents
0176U	Cytolethal distending toxin B (CdtB) and vinculin IgG antibodies by immunoassay (ie, ELISA)
0178U	Peanut allergen-specific quantitative assessment of multiple epitopes using enzyme-linked immunosorbent assay (ELISA), blood, report of minimum eliciting exposure for a clinical reaction
0180U	Red cell antigen (ABO blood group) genotyping (ABO), gene analysis Sanger/chain termination/conventional sequencing, ABO (ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase) gene, including subtyping, 7 exons
0181U	Red cell antigen (Colton blood group) genotyping (CO), gene analysis, AQP1 (aquaporin 1 [Colton blood group]) exon 1
0182U	Red cell antigen (Cromer blood group) genotyping (CROM), gene analysis, CD55 (CD55 molecule [Cromer blood group]) exons 1-10
0183U	Red cell antigen (Diego blood group) genotyping (DI), gene analysis, SLC4A1 (solute carrier family 4 member 1 [Diego blood group]) exon 19
0184U	Red cell antigen (Dombrock blood group) genotyping (DO), gene analysis, ART4 (ADP-ribosyltransferase 4 [Dombrock blood group]) exon 2
0185U	Red cell antigen (H blood group) genotyping (FUT1), gene analysis, FUT1 (fucosyltransferase 1 [H blood group]) exon 4
0186U	Red cell antigen (H blood group) genotyping (FUT2), gene analysis, FUT2 (fucosyltransferase 2) exon 2
0187U	Red cell antigen (Duffy blood group) genotyping (FY), gene analysis, ACKR1 (atypical chemokine receptor 1 [Duffy blood group]) exons 1-2
0188U	Red cell antigen (Gerbich blood group) genotyping (GE), gene analysis, GYPC (glycophorin C [Gerbich blood group]) exons 1-4
0189U	Red cell antigen (MNS blood group) genotyping (GYPA), gene analysis, GYPA (glycophorin A [MNS blood group]) introns 1, 5, exon 2
0190U	Red cell antigen (MNS blood group) genotyping (GYPB), gene analysis, GYPB (glycophorin B [MNS blood group]) introns 1, 5, pseudoexon 3
0191U	Red cell antigen (Indian blood group) genotyping (IN), gene analysis, CD44 (CD44 molecule [Indian blood group]) exons 2, 3, 6
0192U	Red cell antigen (Kidd blood group) genotyping (JK), gene analysis, SLC14A1 (solute carrier family 14 member 1 [Kidd blood group]) gene promoter, exon 9
0193U	Red cell antigen (JR blood group) genotyping (JR), gene analysis, ABCG2 (ATP binding cassette subfamily G member 2 [Junior blood group]) exons 2-26
0194U	Red cell antigen (Kell blood group) genotyping (KEL), gene analysis, KEL (Kell metallo-endopeptidase [Kell blood group]) exon 8
0195U	KLF1 (Kruppel-like factor 1), targeted sequencing (ie, exon 13)
0196U	Red cell antigen (Lutheran blood group) genotyping (LU), gene analysis, BCAM (basal cell adhesion molecule [Lutheran blood group]) exon 3
0197U	Red cell antigen (Landsteiner-Wiener blood group) genotyping (LW), gene analysis, ICAM4 (intercellular adhesion molecule 4 [Landsteiner-Wiener blood group]) exon 1
0198U	Red cell antigen (RH blood group) genotyping (RHD and RHCE), gene analysis Sanger/chain termination/conventional sequencing, RHD (Rh blood group D antigen) exons 1-10 and RHCE (Rh blood group CcEe antigens) exon 5
0199U	Red cell antigen (Scianna blood group) genotyping (SC), gene analysis, ERMAP (erythroblast membrane associated protein [Scianna blood group]) exons 4, 12

0200U	Red cell antigen (Kx blood group) genotyping (XK), gene analysis, XK (X-linked Kx blood group) exons 1-3
0201U	Red cell antigen (Yt blood group) genotyping (YT), gene analysis, ACHE (acetylcholinesterase [Cartwright blood group]) exon 2

Table 2: Non-Covered Procedure Narratives

The following procedure narratives are investigational (**not covered**) for Commercial Products and for Medicare HMO Blue and Medicare PPO Blue, because they do not meet our Medical Technology Assessment Guidelines [350](#).

	Description
1.	Awise PG: A Proprietary Test Measuring Methotrexate (MTX) Polyglutamates, the Active Metabolites of Methotrexate - not covered for commercial products only
2.	Bee Venom Therapy for Treatment of Patients with Multiple Sclerosis
3.	Biologic Vertebral Reconstruction (Optiplasty including OptiMesh®): Variant of Percutaneous Kyphoplasty, a Minimally Invasive Procedure to Treat Spinal Compression Fractures
4.	Bispectral Index (BIS®) Monitoring for Anesthesia Awareness
5.	Bone Lesion Biomechanical Analysis
6.	Brain Electrical Activity Mapping (BEAM)
7.	Carotid Body Resection (glomectomy) – (without tumor)
8.	Chemical aversion to Therapy for the Treatment of Alcoholism – not covered for commercial products only
9.	Cooling caps including but not limited to DigniCap® for preventing hair loss in patients undergoing chemotherapy
10.	Cognitive Enhancement Therapy (CET)
11.	Craniosacral Therapy
12.	Cryosurgical Ablation of Presacral Tumors
13.	Cytotoxic Food Testing
14.	Derma Pal
15.	DecisionDx Melanoma Test – not covered for commercial products only
16.	Diagnostic Ultrasound of Sinuses
17.	Digital Motion X-ray
18.	Disposable Sleep Apnea Screener (Accutest®)
19.	Dry Hydromassage Therapy
20.	Echocardiogram, PORTABLE; Phonocardiogram
21.	Endometrial Function Test (EFT)
22.	Food Immune Complex Assay
23.	ForeCYTE Breast Health Test
24.	Gene Expression Profiling for Uveal Melanoma
25.	Healing-Response Treatment for ACL Injuries
26.	Hereditary Spastic Paraplegia Evaluation
27.	High Intensity Focused Ultrasound (HIFU) for the Treatment of Atrial Fibrillation
28.	Home Telemetry
29.	Home Breath Test Kit
30.	Horizontal Therapy
31.	Hyperthermic Isolated Liver Perfusion
32.	H-wave Electrical Stimulation – based on archived MPRM
33.	Inform Tx Therapeutic Drug Monitoring and Antibody Testing
34.	IgG Allergy Testing
35.	IgA Allergy Testing
36.	Immunoaugmentative Therapy
37.	Implantation of an Electric Urinary Incontinence Device
38.	Injection of Hydrocele with Sclerosing Agent
39.	Intravascular Doppler Technique for Monitoring Renal Venous Blood Flow

40.	KneeHab XP
41.	Kymriah (tisagenlecleucel) – see medical policy #455 Adoptive Immunotherapy
42.	Liver Iron Measurement by MRI (R2 [transverse relaxation rate] MRI; Ferriscan)
43.	Microsurgical Lymphaticovenous Anastomosis for Treatment of Lymphedema
44.	MxA Assay (neutralizing antibodies to IFN β)
45.	NabFeron (neutralizing antibodies to IFN β)
46.	Non-invasive Optimal Vessel Analysis (NOVA)
47.	OrthoCor™ Active Knee System™
48.	PainShield MD™
49.	Pancreatic Polypeptide Test
50.	Parathyroid Cryogenic Preservation and Reimplantation following Cryopreservation
51.	Percutaneous Ablation of a Mass with Ethanol Injection
52.	Percutaneous Ablation of Hepatic Tumors with Ethanol Injection
53.	Percutaneous Ablation of Osteoma with Ethanol Injection
54.	Percutaneous Ablation of Paraspinal Hemangiomas with Ethanol Injection
55.	Percutaneous Ablation of Renal Cyst with Ethanol Injection
56.	Placenta encapsulation i.e. placenta pills or placenta capsules
57.	Provocative Food Testing – Based on NCD 110.11
58.	Pulsed Radiofrequency Treatment of Severe Radicular Pain
59.	Radiofrequency Ablation of the Sphenopalatine Ganglia for the Treatment of Migraine
60.	Radiofrequency Ablation of Tumors of the Kidney
61.	Radiofrequency Treatment of Suprascapular Neuralgia
62.	Renuva Allograft Adipose Matrix
63.	Repair of Bronchial Fistula with Fibrin Glue
64.	Rolling Thermal Scan
65.	Roux-en-Y Pancreaticojejunostomy
66.	Salitron System for Sjorgren's Syndrome
67.	Salivary Cortisol Test
68.	Secretin Hormone for Therapeutic Use: (i.e. other specified early childhood psychoses and autism)
69.	SEDASYS® System for Use by Physician/Nurse Teams to Administer Minimal-to-Moderate Propofol Sedation
70.	ShuntCheck™ Test
71.	Skin Contact Monochromatic Infrared Energy (MIRE)
72.	SonoCine Adjunctive Breast Ultrasound System Model 100
73.	Thoracic-Lumbo-Sacral Orthosis with Pneumatics – based on archived MPRM
74.	Trager Approach: Innovative Approach to Movement Education Utilizing Gentle Non-intrusive Natural Movements
75.	Transcutaneous Electrical Stimulation of the Ear
76.	Transoral Gastroplasty (TOGA®) System for Gastric Stapling
77.	Treatment of Chronic Cerebrospinal Venous Insufficiency (Also known as Liberation Treatment)
78.	Vaginal Cylinder Application of Electronic Brachytherapy
79.	VerifyNow System for Anti-Platelet Therapy: VerifyNow Aspirin Test, VerifyNow P2Y12 Test and VerifyNow IIb/IIIa Test
80.	Video-assisted Bilateral Pulmonary Vein Isolation and Left Atrial Appendage Exclusion for Atrial Fibrillation
81.	VisionScope Endoscopic Camera System
82.	VIVAER Radiofrequency Ablation for Treatment of Nasal Obstruction
83.	ViziLite Oral Identification System
84.	WheatZoomer Test
85.	Yescarta (axicabtagene ciloleucel), immunotherapy called CAR T-cell therapy for treatment of adult patients with relapsed or refractory large B-cell lymphoma – covered effective November 7, 2017 . For medically necessary indications, see policy #066 Chimeric Antigen Receptor Therapy for Hematologic Malignancies .

Table 3: Non-Covered HCPCS Codes and Code Descriptions

The following HCPCS codes are investigational (not covered) for Commercial Products and for Medicare HMO Blue and Medicare PPO Blue, because they do not meet our Medical Technology Assessment Guidelines [350](#).

HCPCS codes	Code Description
A4555	Electrode/transducer for use with electrical stimulation device used for cancer treatment, replacement only
A4563	Rectal control system for vaginal insertion, for long term use, includes pump and all supplies and accessories, any type each
A4600	Sleeve for intermittent limb compression device, replacement only, each
A4639	Replacement pad for infrared heating pad system, each
A7047	Oral interface used with respiratory suction pump, each
A9589	Instillation, hexaminolevulinat hydrochloride, 100 mg
A9597	Positron emission tomography radiopharmaceutical, diagnostic, for tumor identification, not otherwise classified
A9598	Positron emission tomography radiopharmaceutical, diagnostic, for non-tumor identification, not otherwise classified
B4105	In-line cartridge containing digestive enzyme(s) for enteral feeding, each
C1734	Orthopedic/device/drug matrix for opposing bone-to-bone or soft tissue-to bone (implantable)
C1824	Generator, cardiac contractility modulation (implantable)
C1839	Iris prosthesis
C1982	Catheter, pressure-generating, one-way valve, intermittently occlusive
C2596	Probe, image-guided, robotic, waterjet ablation
C2623	Catheter, transluminal angioplasty, drug-coated, non-laser
C8937	Computer-aided detection, including computer algorithm analysis of breast MRI image data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation (list separately in addition to code for primary procedure)
C9751	Bronchoscopy, rigid or flexible, transbronchial ablation of lesion(s) by microwave energy, including fluoroscopic guidance, when performed, with computed tomography acquisition(s) and 3-d rendering, computer-assisted, image-guided navigation, and endobronchial ultrasound (ebus) guided transtracheal and/or transbronchial sampling (eg, aspiration[s]/biopsy[ies]) and all mediastinal and/or hilar lymph node stations or structures and therapeutic intervention(s)
C9752	Destruction of intraosseous basivertebral nerve, first two vertebral bodies, including imaging guidance (e.g., fluoroscopy), lumbar/sacrum
C9753	Destruction of intraosseous basivertebral nerve, each additional vertebral body, including imaging guidance (e.g., fluoroscopy), lumbar/sacrum (list separately in addition to code for primary procedure)
C9754	Creation of arteriovenous fistula, percutaneous; direct, any site, including all imaging and radiologic supervision and interpretation, when performed and secondary procedures to redirect blood flow (e.g., transluminal balloon angioplasty, coil embolization, when performed)
C9755	Creation of arteriovenous fistula, percutaneous using magnetic-guided arterial and venous catheters and radiofrequency energy, including flow-directing procedures (e.g., vascular coil embolization with radiologic supervision and interpretation, when performed) and fistulogram(s), angiography, venography, and/or ultrasound, with radiologic supervision and interpretation, when performed
C9757	Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and excision of herniated intervertebral disc, and repair of

	annular defect with implantation of bone anchored annular closure device, including annular defect measurement, alignment and sizing assessment, and image guidance; 1 interspace, lumbar
C9758	Blinded procedure for nyha class iii/iv heart failure; transcatheter implantation of interatrial shunt or placebo control, including right heart catheterization, trans-esophageal echocardiography (tee)/intracardiac echocardiography (ice), and all imaging with or without guidance (e.g., ultrasound, fluoroscopy), performed in an approved investigational device exemption (ide) study
C9760	Non-randomized, non-blinded procedure for nyha class ii, iii, iv heart failure; transcatheter implantation of interatrial shunt or placebo control, including right and left heart catheterization, transeptal puncture, trans-esophageal echocardiography (tee)/intracardiac echocardiography (ice), and all imaging with or without guidance (e.g., ultrasound, fluoroscopy), performed in an approved investigational device exemption (ide) study
C9762	Cardiac magnetic resonance imaging for morphology and function, quantification of segmental dysfunction; with strain imaging
C9763	Cardiac magnetic resonance imaging for morphology and function, quantification of segmental dysfunction; with stress imaging
G0726	Blinded procedure for lumbar stenosis, percutaneous image-guided lumbar decompression (pild) or placebo-control, performed in an approved coverage with evidence development (ced) clinical trial not covered for commercial products only
G2170	Percutaneous arteriovenous fistula creation (avf), direct, any site, by tissue approximation using thermal resistance energy, and secondary procedures to redirect blood flow (e.g., transluminal balloon angioplasty, coil embolization) when performed, and includes all imaging and radiologic guidance, supervision and interpretation, when performed
G2171	Percutaneous arteriovenous fistula creation (avf), direct, any site, using magnetic-guided arterial and venous catheters and radiofrequency energy, including flow-directing procedures (e.g., vascular coil embolization with radiologic supervision and interpretation, wen performed) and fistulogram(s), angiography, enography, and/or ultrasound, with radiologic supervision and interpretation, when performed
E0221	Infrared heating pad system
E0765	FDA-approved nerve stimulator with replaceable batteries for treatment of nausea and vomiting
E2120	Pulse generator system for tympanic treatment of inner ear endolymphatic fluid
J0591	Injection, deoxycholic acid, 1 mg
J3570	Laetrile, amygdalin, vitamin B-17
K1004	Low frequency ultrasonic diathermy treatment device for home use, includes all components and accessories
L2006	Knee ankle foot device, any material, single or double upright, swing and/or stance phase microprocessor control with adjustability, includes all components (e.g., sensors, batteries, charger), any type activation, with or without ankle joint(s), custom fabricated
M0075	Cellular therapy
S8092	Electron beam computed tomography (also known as ultrafast CT, cine CT)
S9056	Coma stimulation, per diem – based on archived MPRM
S9117	Back school, per visit – based on archived MPRM
Y6240	FDA Investigational Devices
Q3014	Tele-health originating site facility fee – not covered for commercial products only
Q9950	Injection, sulfur hexafluoride lipid microspheres, per ml

This document is designed for informational purposes only and is not an authorization, or an explanation of benefits, or a contract. Receipt of benefits is subject to satisfaction of all terms and conditions of the coverage. Medical technology is constantly changing, and we reserve the right to review and update our policies periodically.

©2020 Blue Cross and Blue Shield of Massachusetts, Inc. All rights reserved. Blue Cross and Blue Shield of Massachusetts, Inc. is an Independent Licensee of the Blue Cross and Blue Shield Association.